As the sector matures, ArentFox Schiff’s new practice reflects growing demand for legal strategies tailored to healthspan science.
Recently, we brought you the news that law firm ArentFox Schiff has launched what it describes as a first-of-its-kind Longevity & Healthspan Industry Group – an initiative designed to provide integrated legal counsel to companies operating across the increasingly complex longevity ecosystem. The move reflects a broader shift taking place across the sector, where businesses built around aging biology rarely sit comfortably within traditional legal categories such as healthcare, life sciences or consumer technology.
Longevity ventures often operate at the intersections – diagnostics, clinical services, AI-driven analytics, wellness products and preventive care may all exist within a single platform. That hybrid structure has begun to expose a practical gap: the need for legal strategies that understand the science of aging and the unusual commercial models emerging around it.
Longevity.Technology: Longevity likes to imagine its hardest problems live at the bench – the stubborn pathways, the noisy biomarkers, the maddening gap between mice and meaning; yet, increasingly, the real bottleneck isn’t always biology – it’s translation: turning clever mechanistic insights into products, clinics and platforms that can survive contact with regulators, investors and, crucially, patients. That is why a dedicated Longevity & Healthspan Industry Group at ArentFox Schiff feels less like belt-and-braces lawyering and more like a maturity marker for the field; as healthspan moves from subculture to sector, claims become the new clinical endpoints – and the new tripwire – because the moment you promise to slow aging rather than “support wellness”, you are no longer just telling a story – you are stepping onto a regulated playing field. Guardrails, in other words, are not the enemy of innovation; they are what makes scale possible without the inevitable pile-up of enforcement actions, reputational damage and consumer distrust. To find out more about where longevity companies are most likely to misstep – and what building responsibly actually looks like in practice – we sat down with Gayland O Hethcoat II, who leads ArentFox Schiff’s newly established group to discuss regulation, data, IP and the risks hiding in plain sight.
Why longevity needs its own legal playbook
At first glance, the creation of a dedicated longevity practice might appear unnecessary in a legal landscape already dense with life sciences expertise. Hethcoat argues the opposite. The issue, he says, is not the absence of lawyers but the absence of strategies designed around the peculiar structure of longevity businesses.
“What ArentFox Schiff saw in the market was not a lack of lawyers, but a lack of legal strategy calibrated to the way longevity businesses actually operate,” he tells us. “Many firms have strong healthcare, life sciences and technology practices – but longevity companies often span all three.”
That convergence matters. A single longevity platform might include biomarker testing, personalized recommendations generated by AI models, physician oversight and consumer-facing wellness products – each bringing different regulatory frameworks into play.
“Our Longevity & Healthspan Industry Group is designed around that ecosystem reality,” he explains. “We bring together regulatory, privacy, IP, corporate and public policy capabilities to help clients design business models that can scale within – and sometimes help shape – evolving legal frameworks.”
Where regulation and science collide
If the sector’s scientific ambitions are clear, the regulatory boundaries are less so. Several areas are emerging as friction points between rapid innovation and slower-moving policy.
“The sharpest collisions are emerging where novel technologies and delivery models outpace clear regulatory boundaries,” Hethcoat says.
Artificial intelligence is one example. As algorithms move from passive analytics toward prescriptive health guidance, questions about liability begin to surface. “AI-driven health recommendations raise unresolved liability questions as systems shift from analysis to prediction and guidance,” he points out.
The peptide market is another flashpoint. Rapid growth has drawn attention from regulators concerned about quality control and marketing practices. “In the peptide space, we are seeing quality-control and marketing issues that are inviting not just FDA scrutiny but enforcement from state medical boards and attorneys general under consumer protection and practice-of-medicine theories,” he says.
Wearables present their own complexities. Devices designed for performance or wellness increasingly approach clinical territory, blurring regulatory definitions. Hethcoat points to the ongoing dispute between WHOOP and the FDA over blood pressure monitoring features as an example of how quickly those boundaries can become contested.
The compliance questions beneath the science
Longevity interventions often exist in a gray zone between prevention, optimization and therapy – and that ambiguity translates directly into compliance risk.
“The threshold questions we assist our clients in answering are often deceptively simple,” Hethcoat explains. “Are you practicing medicine or another licensed profession? Are you marketing a product that falls within FDA jurisdiction? Are your claims framed in a way that triggers consumer protection scrutiny?”
Companies frequently describe offerings in terms of lifestyle improvement or performance optimization, yet rely on clinical biomarkers, physician oversight or medical data. Those elements can quietly pull a product into healthcare regulation.
“The risk is less about bad intent and more about category confusion,” he says. “Businesses that carefully define their product or service and claims – and align those with the appropriate regulatory regime – are far better positioned to innovate without inviting enforcement.”
Intellectual property in aging biology
Intellectual property strategies in longevity face a distinct challenge: the underlying biology of aging is widely studied and frequently shared across academic and commercial research.
“In longevity, IP strategy must balance defensibility with interoperability,” Hethcoat says. “Much of the underlying biology involves shared pathways and mechanisms.”
As a result, companies often find value not solely in patents but in layered strategies that combine multiple forms of protection.
“We encourage clients to think beyond patents alone,” he explains. “Trade secrets, proprietary datasets and carefully structured collaborations can all form part of a defensible position.”
That approach may help prevent a different problem – the creation of dense patent landscapes that slow innovation through overlapping claims and fragmented ownership.
“Thoughtful licensing and joint development agreements can help avoid innovation getting trapped in patent thickets while still protecting the core assets that drive valuation,” he says.
Data at the heart of the healthspan economy
Data governance represents another structural challenge for longevity companies. Many of the most valuable datasets in the field – wearable signals, genetic information and longitudinal biomarker profiles – exist outside traditional medical privacy frameworks.
“HIPAA remains an important baseline,” Hethcoat says, “but it governs only a fraction of the data that fuels the longevity ecosystem.”
That leaves companies navigating a complex patchwork of state privacy laws while simultaneously exploring new economic models built around health data.
“We are seeing serious discussion about the monetization of health data through research partnerships, consumer-permissioned data exchanges and other mechanisms,” he explains.
Such models raise new questions about consent, compensation and secondary data use. Legislative proposals such as the Health Information Privacy Reform Act suggest policymakers are beginning to consider these challenges more directly.
“What companies need is not simply more regulation,” Hethcoat says, “but clearer, harmonized rules around ownership, use rights and accountability for continuous healthspan data.”
The risk hiding in plain sight
Asked which legal risks are most underappreciated, Hethcoat points not to a specific technology but to a mindset.
“The most under-appreciated risk is the tendency for companies to underestimate how their business model is perceived through a regulatory lens,” he says.
Longevity companies often evolve quickly, adding new features, partnerships or services as they grow. Each change can subtly shift how regulators interpret the business.
“Small shifts in claims, partnerships or product features can materially change a company’s risk profile,” he explains. “The companies most likely to face disruption will be those that scale quickly without revisiting these assumptions.”
Periodic reassessment, he suggests, is essential. “The businesses that fare best are the ones that stress-test their model – what exactly are we offering, who is delivering it, what claims are we making and which regulatory regimes might apply if we grow or pivot?”
An industry learning its boundaries
Longevity science is advancing rapidly, but industries mature in stages – discovery, experimentation, translation and finally infrastructure. Legal frameworks tend to emerge in the latter phases, once ideas begin to crystallize into markets and services.
The appearance of dedicated legal practices suggests that the healthspan sector is entering precisely that stage – one where innovation must coexist with accountability, and where the rules of the game are still being written. For the investment community, this move toward formal guardrails provides the “de-risking” necessary to transition longevity from a speculative frontier into a mature, scalable industry.
Quiet progress. Necessary scaffolding.
READ MORE: Longevity gets its own legal playbook at ArentFox Schiff
